Alisa M. Goldstein

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases

  Journal of bone oncology · 2026-06-03

• Supplementary Legend 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  2025-11-25

• Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development

  Med · 2025-11-18 · 1 citations

• Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With <i>TERT</i> Promoter Variant

  JCO Precision Oncology · 2025-09-01

• Clinicopathologic Features, Management, and Outcomes Of Pediatric <i>CRTC1::TRIM11</i> and <i>MED15::ATF1</i> Tumors With Spitzoid Morphology: A Case Series

  Pediatric Blood & Cancer · 2025-05-19 · 8 citations

• Supplementary Table S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

  2024-11-01

• Supplementary Table S5 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

  2024-11-01

• Supplementary Figure S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous CarcinogenesisPreprint

  2024-11-01

• Supplementary Table S1 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

  2024-11-01

• Supplementary Figure S5 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous CarcinogenesisPreprint

  2024-11-01

• Supplementary Figure S8 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous CarcinogenesisPreprint

  2024-11-01

• Supplementary Table S3 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

  2024-11-01

• Supplementary Figure S4 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous CarcinogenesisPreprint

  2024-11-01

• Supplementary Figure S3 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous CarcinogenesisPreprint

  2024-11-01

• Supplementary Table S4 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

  2024-11-01